GlassScriptPhysician profile
Jacob Green
NPI 1669921789
$1,484.52
in general payments reported to CMS, 2019-2025
25 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $266 · 2023: $292 · 2024: $372 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $323.69 | 2022-2024 | Mako, Alphavent, Cinchlock |
| Pacira Pharmaceuticals Incorporated | $134.39 | 2021-2024 | Exparel, Iovera, Zilretta |
| Bioventus LLC | $112.20 | 2021-2024 | Durolane, Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Acera Surgical, INC. | $91.22 | 2022 | |
| Aveo Pharmaceuticals, INC. | $82.36 | 2024-2025 | |
| Pfizer INC. | $72.66 | 2024-2025 | |
| Amgen INC. | $62.68 | 2024-2025 | Evenity, Prolia |
| Eisai INC. | $58.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.60 | 2024-2025 | Enhertu, Imfinzi |
| Array Biopharma INC | $54.05 | 2024-2025 | Xalkori, Braftovi, Lorbrena |
| Incyte Corporation | $49.92 | 2025 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $49.06 | 2024 | Provenge |
| Pacira Therapeutics, INC. | $47.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.20 | 2025 | Ninlaro |
| Karyopharm Therapeutics INC. | $38.34 | 2025 | Xpovio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.26 | 2025 | Libtayo |
| Treace Medical Concepts, INC. | $28.16 | 2024 | |
| Merck Sharp & Dohme LLC | $24.44 | 2024 | Keytruda |
| Vericel Corporation | $23.48 | 2024 | Maci |
| Exelixis INC. | $21.90 | 2025 | Cabometyx |
| Innovation Technologies INC | $19.32 | 2022 | |
| Gilead Sciences, INC. | $18.55 | 2025 | Trodelvy |
| Depuy Synthes Sales INC. | $15.83 | 2023 | Monovisc, Orthovisc |
| Pylant Medical | $14.97 | 2022 | |
| Geron Corporation | $14.21 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.